Does a higher milligram count on a supplement label mean better bioavailability?

No. The milligram count refers to the amount placed in the capsule before absorption — it does not reflect what your body actually absorbs. Bioavailability depends on the specific form of the ingredient (the chemical salt or complex used), not just the amount. A supplement with 50 mg of zinc as zinc picolinate may deliver more absorbable zinc than 50 mg as zinc oxide, because the form determines how much of the listed amount reaches systemic circulation. The label does not show you this fraction.

How is bioavailability measured in clinical studies?

The most common methods are: area under the curve (AUC) from serial plasma measurements — which reflects total systemic exposure over a time period; Cmax (peak plasma concentration); urinary excretion as a proxy for absorbed fraction (used for minerals excreted proportionally to intake); and stable isotope tracing, which labels the administered dose and allows direct measurement of the absorbed fraction. The most rigorous studies use crossover designs, where the same subjects receive each formulation in sequence, so between-person variation is controlled.

Can food affect supplement bioavailability?

Yes, significantly for some nutrients. Phytic acid (found in grains, legumes, and nuts) binds minerals including zinc, iron, and magnesium in the gut and reduces their absorption. Fat-soluble vitamins (A, D, E, K) require dietary fat for absorption and should generally be taken with a meal containing fat. Calcium competes with zinc and iron for intestinal transporters, so high-calcium meals can reduce absorption of other minerals. Conversely, vitamin C enhances non-heme iron absorption. Timing relative to food is a practical bioavailability consideration for several nutrients.

Why does supplement form affect bioavailability so much?

The form determines how well the ingredient dissolves in the gut, which transporters it can use to cross the intestinal wall, and whether it survives liver metabolism before reaching the bloodstream. Mineral chelates (like zinc picolinate or magnesium glycinate) exploit amino acid transport pathways that are distinct from — and often more efficient than — standard mineral uptake routes. Inorganic salts like zinc oxide have limited solubility at higher pH, constraining lumen availability regardless of dose. These differences are documented in human pharmacokinetic studies and explain why form-specific bioavailability can vary several-fold for the same labeled milligram count.

Is there a minimum bioavailability percentage I should look for in a supplement?

There is no universal minimum — what constitutes adequate bioavailability depends on the ingredient, the dose, and what effect you are trying to achieve. The more useful approach is to evaluate whether the specific form in the product has published human pharmacokinetic data showing meaningful systemic absorption, and whether the amount per serving is likely to achieve a systemic concentration in the range where research has observed the relevant effect. For some ingredients (e.g., magnesium oxide), even widely available bioavailability data suggests the form underperforms relative to alternatives. Work with your physician to determine what's appropriate for your individual situation.

Bioavailability: What It Actually Means for Your Supplements (and Why Most Labels Lie by Omission)

6 sectionsUpdated June 2026Reviewed by Dr. Brennan Commerford, D.C.

Quick Answer

What does 'bioavailability' mean for a supplement, and why does it matter?

Bioavailability is the fraction of an ingested compound that reaches systemic circulation in an active form. For supplements, it is the single most important number the label never shows you. Two bottles that both say 'Zinc 50 mg' can deliver very different amounts of absorbable zinc depending on the salt form used. A 1987 double-blind crossover trial in Agents and Actions (Barrie et al., PMID 3630857) found that zinc picolinate produced significantly higher tissue zinc levels than zinc citrate or zinc gluconate at the same elemental dose. A 2005 randomized crossover pharmacokinetic study (Siepmann et al., PMID 16372518) found that zinc gluconate produced 18.3% higher peak plasma zinc (Cmax) than zinc oxide in healthy men. Neither comparison appears on any product label. Understanding bioavailability is the prerequisite for evaluating whether a supplement can actually do what the marketing promises.

What Bioavailability Actually Means

Bioavailability is a pharmacokinetic term that describes the fraction of an administered dose that reaches systemic circulation in an active form. For a supplement taken by mouth, that means: of the total amount swallowed, what percentage actually enters the bloodstream at a concentration that tissues can use?

The number accounts for everything that can go wrong along the way: dissolution in the stomach, absorption across the intestinal wall, first-pass metabolism in the liver, and chemical stability throughout that journey. A compound with 60% bioavailability means roughly 60 mg out of every 100 mg swallowed reaches circulation — and the other 40 mg is lost before it can reach a single cell.

For pharmaceutical drugs, bioavailability is studied, disclosed, and used to calculate therapeutic doses. For dietary supplements, it is studied in the academic literature but is not required to appear anywhere on the product label. The milligram count consumers use to compare products reflects only the amount placed in the capsule before bioavailability is applied — not the amount their body will actually receive.

This gap between labeled dose and absorbed dose is the core reason supplement form matters. It is also the gap the industry largely counts on consumers not closing.

Why the Label Tells You Almost Nothing About Bioavailability

The Supplement Facts panel is governed by FDA labeling regulations that require disclosure of: the ingredient name, the serving size, the amount per serving, and a percentage of the Daily Value (where applicable). There is no regulatory requirement to disclose bioavailability percentage, absorption fraction, or the specific salt form's pharmacokinetic profile.

This creates a structural information gap. Consider two zinc supplements on the same shelf:

- Supplement A: "Zinc 50 mg (as Zinc Oxide)" - Supplement B: "Zinc 50 mg (as Zinc Picolinate)"

Both labels are legally complete. Both claim 50 mg of zinc. A consumer comparing them on milligrams and price will likely choose whichever is cheaper. The label does not tell them that a 1987 double-blind crossover trial published in Agents and Actions (Barrie SA et al., PMID 3630857) found zinc picolinate produced significantly higher tissue zinc concentrations — measured in hair, urine, and erythrocytes — than zinc gluconate at the same elemental dose, while zinc gluconate produced no significant increase over placebo in those markers.

The label also does not tell them that a 2005 randomized crossover pharmacokinetic study published in the International Journal of Clinical Pharmacology and Therapeutics (Siepmann et al., PMID 16372518) found that zinc gluconate produced a mean Cmax 18.3% higher than zinc oxide and an AUC(0–24h) 8.1% higher at equivalent doses in 12 healthy male subjects. Zinc oxide — the least expensive, most common form — produced the lowest absorption response in that study.

The information is in the peer-reviewed literature. The label has no mechanism to show it.

Barrie SA et al. Agents Actions. 1987;21(1-2):223-8. PMID 3630857Siepmann M et al. Int J Clin Pharmacol Ther. 2005;43(12):562-5. PMID 16372518

See which magnesium forms score highest for effective dose

View rankings

Form Is the Biggest Lever: Zinc as a Case Study

Zinc is one of the most extensively studied minerals for form-specific bioavailability, making it a useful illustration of how much absorption can vary by the salt used as the carrier.

The 1987 double-blind, four-period crossover trial by Barrie et al., published in Agents and Actions (PMID 3630857), enrolled 15 healthy human volunteers and rotated them across zinc picolinate, zinc citrate, zinc gluconate, and placebo over four-week periods, each providing 50 mg elemental zinc per day. At the end of each period, tissue zinc was measured in hair, urine, and erythrocytes. Hair, urinary, and erythrocyte zinc levels rose significantly during zinc picolinate supplementation (p < 0.005, p < 0.001, and p < 0.001 respectively). No significant change was observed from zinc gluconate, zinc citrate, or placebo in those same markers.

The 2005 randomized crossover pharmacokinetic study by Siepmann et al., published in the International Journal of Clinical Pharmacology and Therapeutics (PMID 16372518), compared zinc gluconate against zinc oxide in 12 healthy men over 14-day dosing periods. Zinc plasma concentrations were measured by inductively coupled plasma-atomic emission spectroscopy — a validated quantitative method. Mean Cmax was 18.3% higher (95% CI: 10.3–26.3%) after zinc gluconate compared to zinc oxide (p < 0.05). AUC(0–24h) was 8.1% higher (95% CI: 1.9–14.3%) for gluconate versus oxide (p < 0.05).

Together these studies illustrate the gradient: zinc picolinate > gluconate > oxide in absorption-relevant outcomes. All three forms are sold under the same "Zinc" designation on supplement labels.

Work with your physician before changing zinc supplementation, particularly if you are managing a health condition or taking medications. These ingredients are not a substitute for professional medical advice, diagnosis, or treatment.

Barrie SA et al. Agents Actions. 1987;21(1-2):223-8. PMID 3630857Siepmann M et al. Int J Clin Pharmacol Ther. 2005;43(12):562-5. PMID 16372518

The Five Factors That Determine Bioavailability

Bioavailability is not a fixed property of an ingredient — it is the outcome of multiple interacting factors. Understanding them helps explain why the same compound can have very different absorption profiles across products.

**1. Solubility and dissolution rate.** A compound must dissolve in the gut lumen before it can cross the intestinal wall. Insoluble or poorly soluble forms may pass through largely intact, particularly when gastric acid production is reduced (which becomes more common with age). Zinc oxide, for example, has limited solubility at higher gastric pH, which constrains the amount available for absorption regardless of dose.

**2. Intestinal transport mechanisms.** The small intestine uses a combination of passive diffusion and active carrier-mediated transport to absorb compounds. Chelated mineral forms — where the mineral is bound to an amino acid ligand — can exploit amino acid transport pathways that operate independently of the standard mineral uptake route. This bypasses transporter saturation that limits inorganic salt absorption at higher doses.

**3. First-pass hepatic metabolism.** After crossing the gut wall, compounds enter the portal circulation and pass through the liver before reaching systemic blood. The liver may metabolize some fraction of a compound before it reaches the tissues where it acts. First-pass metabolism is the primary reason some compounds have dramatically lower oral bioavailability than intravenous bioavailability.

**4. Food co-ingestion.** Dietary composition at the time of supplementation significantly affects absorption for many compounds. Phytic acid in plant foods binds minerals (including zinc, iron, and magnesium) in the gut and reduces their absorption. Fat-soluble vitamins (A, D, E, K) require dietary fat for micellar solubilization and absorption. Some nutrients compete for the same transporters, so timing relative to meals and other supplements matters.

**5. Individual variation.** Genetics (including variants in transporter genes), gut microbiome composition, age, gastrointestinal health, and the presence of conditions affecting gut transit all influence how much of any compound an individual actually absorbs. Population-level pharmacokinetic averages represent central tendencies, not guarantees for any individual.

The interaction of these factors is why bioavailability research uses controlled crossover designs — holding diet, health status, and dose constant to isolate the form-specific variable.

What This Means for Evaluating Supplements

For a consumer trying to evaluate whether a supplement is likely to work, the milligram count on the label is a starting point — but it is not the full picture. Form-specific bioavailability is the multiplier the label doesn't show.

Evaluating form-specific bioavailability requires looking at the peer-reviewed pharmacokinetic literature for the specific salt or compound form being sold. The useful question is not "how many milligrams is this?" but "at this dose of this specific form, what does published human PK data say about the absorbed fraction relative to comparator forms?"

For ingredients where bioavailability varies substantially by form — zinc, magnesium, coenzyme Q10, curcumin, and others — the form often matters as much as the dose for determining whether a supplement can reach a tissue at a relevant concentration.

No supplement label is required to answer this question for you. The peer-reviewed literature contains the data. The challenge is accessing and interpreting it, which requires either substantial time or a formulation system that applies the research systematically.

These statements have not been evaluated by the Food and Drug Administration. This information is provided for educational purposes and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before beginning any supplement program.

Deeper Dive

Deeper Dive: How Pharmacokinetic Studies Measure Bioavailability

Understanding how bioavailability is measured in human studies helps evaluate the quality of evidence behind any bioavailability claim.

**Area under the curve (AUC).** After a supplement is taken, blood samples are collected at intervals and the compound concentration in plasma is measured. Plotting concentration against time produces a curve; the area under that curve reflects total systemic exposure. Higher AUC means more of the compound reached circulation over the measurement period. AUC is the standard endpoint for comparing bioavailability between two formulations — if AUC is 20% higher for Form A versus Form B at the same labeled dose, Form A delivered 20% more to systemic circulation.

**Cmax (peak plasma concentration).** The highest plasma concentration reached after a dose. Cmax reflects how high a concentration is achieved at any point — which may or may not be the most clinically relevant measure depending on the compound. For compounds that work best above a threshold concentration (e.g., many anti-inflammatory botanicals), Cmax can be as important as AUC.

**Urinary excretion.** For minerals eliminated primarily through the kidneys at rates proportional to intake, urinary excretion can serve as a validated proxy for intestinal absorption. The Barrie et al. 1987 trial (PMID 3630857) used urinary zinc as a measure of systemic zinc exposure — higher urinary zinc reflects more absorbed zinc.

**Stable isotope tracing.** The gold-standard method uses isotopically labeled versions of the mineral or compound (e.g., zinc-67 or iron-58) to track absorption precisely. Stable isotope studies allow researchers to distinguish the test compound from endogenous mineral levels. This method avoids confounders from background mineral status and gives direct absorption fractions.

**Crossover design.** The most rigorous bioavailability comparisons use crossover designs, where the same subjects receive each formulation in sequence with a washout period in between. This controls for between-subject variation in gut physiology, diet, and baseline mineral status — the same individual becomes their own control, making the comparison direct.

The 2005 Siepmann et al. study (PMID 16372518) used a randomized crossover design with plasma zinc measured by ICP-AES across 14-day dosing periods — a methodologically rigorous design that produced statistically significant AUC and Cmax differences between zinc gluconate and zinc oxide.

Siepmann M et al. Int J Clin Pharmacol Ther. 2005;43(12):562-5. PMID 16372518

See How FormulaForge Selects Forms

Every ingredient in a FormulaForge formula is evaluated on published bioavailability data — not just the milligram count on the label.

Build Your Formula

Frequently Asked Questions

Does a higher milligram count on a supplement label mean better bioavailability?: No. The milligram count refers to the amount placed in the capsule before absorption — it does not reflect what your body actually absorbs. Bioavailability depends on the specific form of the ingredient (the chemical salt or complex used), not just the amount. A supplement with 50 mg of zinc as zinc picolinate may deliver more absorbable zinc than 50 mg as zinc oxide, because the form determines how much of the listed amount reaches systemic circulation. The label does not show you this fraction.
How is bioavailability measured in clinical studies?: The most common methods are: area under the curve (AUC) from serial plasma measurements — which reflects total systemic exposure over a time period; Cmax (peak plasma concentration); urinary excretion as a proxy for absorbed fraction (used for minerals excreted proportionally to intake); and stable isotope tracing, which labels the administered dose and allows direct measurement of the absorbed fraction. The most rigorous studies use crossover designs, where the same subjects receive each formulation in sequence, so between-person variation is controlled.
Can food affect supplement bioavailability?: Yes, significantly for some nutrients. Phytic acid (found in grains, legumes, and nuts) binds minerals including zinc, iron, and magnesium in the gut and reduces their absorption. Fat-soluble vitamins (A, D, E, K) require dietary fat for absorption and should generally be taken with a meal containing fat. Calcium competes with zinc and iron for intestinal transporters, so high-calcium meals can reduce absorption of other minerals. Conversely, vitamin C enhances non-heme iron absorption. Timing relative to food is a practical bioavailability consideration for several nutrients.
Why does supplement form affect bioavailability so much?: The form determines how well the ingredient dissolves in the gut, which transporters it can use to cross the intestinal wall, and whether it survives liver metabolism before reaching the bloodstream. Mineral chelates (like zinc picolinate or magnesium glycinate) exploit amino acid transport pathways that are distinct from — and often more efficient than — standard mineral uptake routes. Inorganic salts like zinc oxide have limited solubility at higher pH, constraining lumen availability regardless of dose. These differences are documented in human pharmacokinetic studies and explain why form-specific bioavailability can vary several-fold for the same labeled milligram count.
Is there a minimum bioavailability percentage I should look for in a supplement?: There is no universal minimum — what constitutes adequate bioavailability depends on the ingredient, the dose, and what effect you are trying to achieve. The more useful approach is to evaluate whether the specific form in the product has published human pharmacokinetic data showing meaningful systemic absorption, and whether the amount per serving is likely to achieve a systemic concentration in the range where research has observed the relevant effect. For some ingredients (e.g., magnesium oxide), even widely available bioavailability data suggests the form underperforms relative to alternatives. Work with your physician to determine what's appropriate for your individual situation.

References

Barrie SA et al. Agents Actions. 1987;21(1-2):223-8. PMID 3630857 PubMed
Siepmann M et al. Int J Clin Pharmacol Ther. 2005;43(12):562-5. PMID 16372518 PubMed

FormulaForge formulates and sells supplements containing the ingredients discussed on this page. Our formulary recommendations are based on peer-reviewed bioavailability research. All cited studies are independently verifiable.